The company says recent research of its Gen2 system suggests the device could generate an eye-watering $8 billion in market revenue in the United States alone, by offering doctors cutting-edge real-time clarity of their patients’ gut health at a cellular level.
The latest technology could potentially reduce the need for multiple biopsies and streamline clinical decision-making, improving on traditional diagnostic methods that can struggle to provide the real-time precision doctors require.
The adoption of its GI endomicroscopy technology could also trigger an estimated additional $9.5 billion in overall healthcare benefits in the US, according to research Optiscan commissioned last year from US-based consultants Latham Biopharm Group
Ann: Optiscan Initiates GI Study in Germany with First Prototype, page-8
Add to My Watchlist
What is My Watchlist?
